Thomas George, Eddie DaRoza, and Scott Willis talk mind altering drugs in our inaugural episode of the Grizzle Psychedelics series.

The upshot of psychedelics is the opportunity to treat addiction (specifically opioids) and depression. We examine the cold hard data in America — it’s clear something radical needs to be done and psychedelics potentially offer a critical tool.

We look at the efficacy of various psychedelics in the treatment of addiction, depression, and anxiety.

To understand the ultimate opportunity of the sector we need to identify the total addressable market for anxiety and depression drugs, and we compare that market to the current addressable market for cannabis.

Lastly, we look at the share structure of MindMed (NEO: MMED) and help investors understand the fundamental hurdles for success of this psychedelic recent share listing. Is this the latest pump and dump, or the real deal.

About Author

The opinions provided in this article are those of the author and do not constitute investment advice. Readers should assume that the author and/or employees of Grizzle hold positions in the company or companies mentioned in the article. For more information, please see our Content Disclaimer.